DEVELOPMENT OF SIMPLE HPLC METHOD TO ESTIMATE THE BLOOD PLASMA CONCENTRATION OF EFAVIRENZ IN RAT AFTER ORAL ADMINISTRATION
Keywords:Efavirenz, Atorvastatin, HPLC, Pharmacokinetics
Objective: The present study was design with an objective of developing a simple and rapid high performance liquid chromatography (HPLC) method for the determination of Efavirenz (EFA) in rat plasma.
Methods: Chromatographic separation was achieved on C18 column using acetonitrile-50 mM potassium phosphate (55:45 v/v) as mobile phase at a flow rate of 1 ml/min and UV detection at 250 nm.
Results: The retention time of EFA was found to be 13.2 min. The developed method was validated for linearity, limit of quantification (LOQ), limit of detection (LOD), Stability and selectivity. Linearity studies were found to be acceptable over the range of 5-50 Î¼g/ml.
Conclusion: The present analytical method was found to be specific, sensitive, accurate and precise for quantification of EFA in rat plasma. It can be successively applied for pharmacokinetics studies also.
Sadler BM, Hanson CD, Chittick GE, Symonds WT, Roskell NS. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother 1999;43:1686-92.
Wu EY, Wilkinson JM, Naret DG, Danields VL, Williams LJ, Khalil DA, et al. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor in human plasma. J Chromatogr B Biomed Sci Appl 1997;695:373-80.
Granda BW, Giancarlo GM, Moltke L, Greenblatt DJ. Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography. J Pharmacol Toxicol Methods 1998;40:235-9.
Hoetelamns RMW, Essenberg M, Meenhorst PL, Mulder JW, Beijnen JH. High-performance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva. J Chromatogr B: Biomed Sci Appl 1998;705:119-26.
Marsh KC, Eiden E, McDonald E. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatogr B: Biomed Sci Appl 1997;704:307-13.
Ha HR, Follath F, Bloemhard YS. Determination of saquinavir in human plasma by high-performance liquid chromatography. J Chromatogr B: Biomed Sci Appl 1997;694:427-33.
Frappier S, Breilh D, Diarte E, Ba D, Ducint D, Pellegrin JL, et al. Simultaneous determination of ritonavir and saquinavir, two human immunodeficiency virus protease inhibitors, in human serum by high-performance liquid chromatography. J Chromatogr B: Biomed Sci Appl 1998;714:384-9.
Hugen PW, Wissen CP, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B: Biomed Sci Appl 1999; 727:139-49.
Moyer TP, Temesgen Z, Enger R, Estes L, Charlson J, Olivier L, et al. Drug Monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem 1999;45:1465-76.
Heeswijk RPG, Hoetelmans RMW, Harms R, Meenhorst PL, Mulder JW, Lange JMA, et al. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B: Biomed Sci Appl 1998;719:159-68.
Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003;73:20-30.
Veldkamp AI, Heeswijk RP, Meenhorst PL, Mulder JW, Lange JM, Beijnen JH, et al. Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B: Biomed Sci Appl 1999;734:55-61.
Langmann P, Schirmer D, Vath T, Zilly M, Klinker H. High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy. J Chromatogr B: Biomed Sci Appl 2001;755:151-6.
Sarasa-Nacenta M, Lopez-Pua Y, Lopez-Cortes LF, Mallolas J, Gatell JM, Carne X. Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B: Biomed Sci Appl 2001;763:53-9.
Matthews CZ, Woolf EJ, Mazenko RS, Wiener H, Chavez CM, Constanzer ML, et al. Determination of efavirenz, a selective non-nucleoside reverse transcriptase inhibitor, in human plasma using HPLC with post-column photochemical derivatization and fluorescence detection. J Pharm Biomed Anal 2002;28:925-34.
Aymard G, Legrand M, Trichereau N, Diquet B. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography. J Chromatogr B: Biomed Sci Appl 2000;744:227-40.
Titier K, Lagrange F, Pehourcq F, Mcheik L, Moore N, Molimard M. Plasmatic dosage of antiretroviral drugs by high performance liquid chromathography. Therapie 2000;57:169-74.
Rezk NL, Tidwell RR, Kashuba ADM. Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection. J Chromatogr B: Anal Technol Biomed Life Sci 2000;774:79-88.
Boffito M, Tija J, Reynolds HE, Hoggard PG, Bonora S, Perri GD, et al. Simultaneous determination of rifampicin and efavirenz in plasma. Ther Drug Monit 2000;24:670-4.
Cociglio M, Buys DH, Peyriere H, Alric R. Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma. Chromatogr Sci Ser 2003;41:80-6.
Usami Y, Oki T, Nakai M, Sagisaka M, Kaneda T. A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz. Chem Pharm Bull 2003;51:715-8.
Kappelhoff BS, Rosing H, Huitema AD, Beijnen JH. Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. J Chromatogr B: Anal 2003;792:353-62.
Keil K, Frerichs VA, DiFrancesco R, Morse G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit 2003;25:340-6.
Dailly E, Raffi F, Jolliet P. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. J Chromatogr B: Anal Technol Biomed Life Sci 2004;813:353-8.
Poirier JM, Robidou P, Jaillon P. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the non nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. Ther Drug Monit 2005;27:186-92.
Takahashi M, Yoshida M, Oki T, Okumura N, Suzuki T, Kaneda T. Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and non nucleoside reverse transcription inhibitor efavirenz in human plasma. Biol Pharm Bull 2005;28:1286-90.